ITEM#: 3113-D5481200MG
MFR#: D5481-200MG
Dolasetron Mesylate Mono 200mg
Product Name | Description | Item# | QTY | |
---|---|---|---|---|
DOLASETRON MESYLATE MONOH 50MG | Dolasetron Mesylate Monoh 50mg | 3113-D548150MG | EA | |
Dolasetron mesylate | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuin | 3042-1224959125MG | EA | |
Dolasetron mesylate Related Compound A | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuin | 3042-122496025MG | EA | |
Dolasetron mesylate hydrate >=98% (HPLC), powder | Dolasetron mesylate hydrate >=98% (HPLC), powder | 3042-D957150MG | EA | |
Dolasetron mesylate hydrate >=98% (HPLC), powder | Dolasetron mesylate hydrate >=98% (HPLC), powder | 3042-D957110MG | EA | |
MONO-2-O-P-TOLUENESULFO 200MG | Mono-2-O-(p-toluenesulfonyl)-beta-cyclodextrin Hydrate, >-97.0% (HPLC), C49H76O37S, CAS Number-84216-71-7, 200mg, White, 1289.17, VGZWDYWXWGKKEE-UJPGXMRNSA-N, Crystal-Powder at 20 deg.C, 11829278 | 3113-M1741200MG | EA | |
MONO-2-O- P-TOLUENESULFONYL M1956-200MG | MONO-2-O- P-TOLUENESULFONYL M1956-200MG - M1956-200MG, 200 mg | 3113-M1956200MG | EA | |
DOXAZOSIN MESYLATE 1G . | DOXAZOSIN MESYLATE 1G - D4126-1G, 1 g | 3113-D41261G | EA | |
RASAGILINE MESYLATE 1G | Rasagiline Mesylate 1g | 3113-R02131G | EA |
Thank you for visiting, your account is pending approval.
You will received email notification for approval within 24hrs.
Contact customerservice@franklinyoung.com for any questions.
Thank you for requesting an account with Franklin Young.
Your request has been declined
We restrict website access to government entities, and related customers.
Please contact customerservice@franklinyoung.com with any questions.